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Background: Chlamydia trachomatis is the most prevalent bacterial sexually transmitted infection (STI) worldwide.
A strong link between C. trachomatis serogroup/serovar and serological response has been suggested in a previous
preliminary study. The aim of the current study was to confirm and strengthen those findings about serological IgG
responses in relation to C. trachomatis serogroups and serovars.
Methods: The study population (n = 718) consisted of two patient groups with similar characteristics of Dutch STI
clinic visitors. We performed genotyping of serovars and used titre based and quantitative commercially available
ELISA kits (medac Diagnostika) to determine specific serum IgG levels. Optical density (OD) values generated by
both tests were used to calculate the IgG titres (cut-off 1:50). Analyses were conducted stratified by gender.
Results: We observed very significant differences when comparing the median IgG titres of three serogroups, B, C
and I: in women for B vs. C: p < 0.0001 (median titres B 200 vs. C <50); B vs. I: p < 0.0001 (200 vs. 50), and in men for
B vs. C: p = 0.0006 (150 vs. <50); B vs. I: p = 0.0001 (150 vs. <50); C vs. I was not significant for both sexes. Serovars D
and E of serogroup B had the highest median IgG titres compared to the other serovars in both men and women:
200 and 200 vs. ≤ 100 for women and 100 and 200 vs. ≤ 75 for men, respectively.
Conclusions: This study shows that B group serovars induce higher serological responses compared to the C and I
group serovars in vivo in both men and women.
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Chlamydia trachomatis is the most prevalent bacterial
sexually transmitted infection (STI) worldwide. The
clinical course of infection is frequently asymptomatic
resulting in patients not seeking treatment. Untreated
urogenital C. trachomatis infections may give rise to late
complications, including pelvic inflammatory disease, ec-
topic pregnancy, and sub- or infertility [1]. Assessment of* Correspondence: samorretravel@yahoo.co.uk
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stated.serological responses to the bacterium resulted in a classi-
fication in serovars [2]. Nowadays, 19 different serovars
are known, usually causing conjunctival and urogenital in-
fections. The serovars are subdivided in three serogroups
based on phylogenetic comparisons of the ompA gene.
Serogroup B contains serovars B, Ba, D, Da, E, L1, L2, L2a;
serogroup C contains: A, C, H, I, Ia, J, K, L3; serogroup I
contains: F, G, Ga [3,4]. Identification and typing of sero-
vars is currently done by rapid PCR-based techniques
[5-7]. Geographical distribution of the serogroups is very
similar worldwide on a national level, but there are varia-
tions in distribution within cities [8,9]. The most prevalent
serovars worldwide are D, E, and F [10,11].
Several studies have shown associations between uro-
genital serovars and severity of clinical symptoms and
the course of C. trachomatis infections [11,12], althoughLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
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been shown that serovar K is associated with abnormal
vaginal discharge, and serovar Ga is associated with
dysuria in men [12]. Van Duynhoven et al. [11] reported
that infections with serovars D/D−, H, and K appeared
to be associated with inflammation, as shown by the
presence of 10 or more leukocytes per microscopic field
(magnification, x400). This was determined in first-void
urine samples from men and in gram-stained cervical
smears from women. However, this was not statistically
significant. A comparison study of serovars D and H in
a murine model shows that serovar H elementary bodies
(EB) are more cytotoxic than EBs of serovar D, but the
serovar D EBs have a longer duration of infection [15].
In all studies however, the B group serovars are most
prevalent and the C group serovars least common, sug-
gesting different immunological responses by the host to
serovars/serogroups. This may be of clinical interest since
an association was observed between higher antibody
responses and severity of tubal pathology [16].
In a previous study [17] we measured immunoglobulin
(Ig) G titres in 235 C. trachomatis infected patients. For
these measurements we used a quantitative ELISA kit
developed by medac Diagnostika. We observed that the
most prevalent serogroup B induced significantly higher
serological IgG responses than serogroups C and I [17].
These results suggest a relation between serovars and
the serological responses in human and potentially offer
a partial explanation of the geographical prevalence of
specific serovars. These results, however, have not been
verified in different patient populations, nor have they
been confirmed using other serological tests.
The aim of this study was to confirm and expand our
previous study concerning serological IgG responses in
relation to C. trachomatis serogroups and serovars. We
used a study population consisting of two different pa-
tient groups and for our experiments we made use of
titre-based and quantitative serological ELISA assays.
We explored whether or not the most prevalent serovars
(D, E, and F) induced the highest serological responses,
in addition to analysing at serogroup level only as has
been done previously [17].
Methods
Patient populations and C. trachomatis detection
The study included samples from 718 C. trachomatis
infected patients, derived from two different patient
groups. The first group (Study 1) was obtained from
357 microbiologically confirmed C. trachomatis patients
(as determined by PACE2 assay, Gen Probe) obtained
from the STI outpatient clinic (n = 312) and the depart-
ment of obstetrics and gynaecology (n = 45) in The Hague,
the Netherlands. The samples include cervical and/or va-
ginal swabs, urethral swabs, and urine specimens. Serumsamples were collected from all patients. These samples
were stored in the period January to October 2008. Rea-
sons for patients visiting either the STI clinic or gynaecol-
ogy department and the collection of demographic data
are described elsewhere [17]. To prevent possible bias in
serological responses we excluded patients with a multiple
site infection or mixed infection, and patients with an in-
fection other than the urethral tract or cervicovaginal tract
(n = 70). A total number of 287 patients (149 women and
138 men) were used for analyses, of which 82 were unique
compared to the previous study [17].
The second patient group (Study 2) included 361
C. trachomatis infected women (as determined by COBAS
AMPLICOR, Hoffman – La Roche, Basel, Switzerland).
Characteristics are described elsewhere [18]. In short, cer-
vical swabs were taken and serum was collected from
women attending an STI outpatient clinic in Amsterdam,
the Netherlands. Demographical and clinical data were
available and informed consent was obtained [18].
Ethnicity in both patient groups was self-reported,
which has been shown a highly valid and representative
marker of ethnicity in this context [19]. Figure 1 shows
a flowchart summarising the in- and exclusion criteria
and the groups analysed.
Ethical approval
The Medical Research Involving Human Subjects Act
(WMO, Dutch Law) stating official approval of the study
by the Medical Ethical Committee does not apply to
our anonymous human material collected (MEC Letter
reference: # 10.17.0046).
C. trachomatis genotyping
Serogroup and serovar determination for Study 1 was
performed with the C. trachomatis-DT assay (Labo Bio-
medical Products BV, Rijswijk, the Netherlands) as de-
scribed elsewhere [8]. Shortly, DNA was extracted from
the swabs and urine samples to detect C. trachomatis for
confirmation of the PACE2 assay. After confirmation,
genotyping was performed using a reverse hybridization
probe line blot with a probe for the cryptic plasmid and
a probe for the three serogroups and all serovars.
C. trachomatis genotyping in Study 2 was performed
by means of PCR based RFLP analyses as described previ-
ously or, for the second half by sequencing the VD2 region
of the ompA gene [20].
C. trachomatis serology
Study 1: determination of C. trachomatis IgG levels in
serum of all patients was done by pELISA (Chlamydia
trachomatis-IgG-ELISA plus kit (medac Diagnostika,
Germany)) and was performed according to the manufac-
turer’s protocols. This is an assay generating quantitative
results (Arbitrary Units/ml), based on OD values. These
Figure 1 The figure shows a flowchart summarising the in- and exclusion criteria and the groups analysed. *: reference [17]. NAAT 1:
PACE2 assay. NAAT 2: COBAS AMPLICOR. Typing 1: C. trachomatis-DT assay. Typing 2: sequencing VD2.
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this study, we calculated the titres to make the results
in accordance with the results of Study 2. Cut-off levels
for negative, grey zone, and positive C. trachomatis
IgG serology were used as described by the manufacturer
(cut-off 1:50).
Study 2: determination of IgG levels was done previously
by Chlamydia trachomatis-IgG-ELISA (medac Diagnostika,
Germany) according to the manufacturer’s protocol.
Titres ≥ 1:50 were considered positive.
Similar titre calculations for both Medac assays
were performed as described by the manufacturer’s
instructions.
Statistical analyses
Since different antibody levels against C. trachomatis have
been described in men and women [21], we analysed men
and women separately, except when stated differently.
Mann–Whitney U tests were used to compare median
titres between the serogroups (B vs. C; B vs. I; C vs. I).
Mann–Whitney U tests were used to compare median
titres of serovars within serogrous. Analyses were per-
formed using Prof. Avery’s ‘utest’ program [22]. P values
< 0.05 were considered statistically significant.Results
Characteristics and serovar distribution between the two
patient groups (Study 1 and 2) were compared. We
compared serological distribution of the serogroups and
serovars, and we compared age between the two individ-
ual patient groups. We did not observe any significant
differences in distribution of serological titres between
both patient groups in total, or between ethnic sub-
groups (general distribution: 57.3% Dutch Caucasian; 8.0%
Surinam; 8.5% Dutch Antilles; 3.8% North African; 2.4%
western European (non Dutch); 2.0% eastern European;
18.0% other nationalities). We observed no differences in
mean age and distribution of the serological titres per ser-
ovar and serogroup between both patient groups in total,
or between the ethnic subgroups. Therefore we combined
both groups and analysed them as one.
Serogroup analyses
The serological titres per serogroup and per serovar are
shown in Table 1 and Figure 2 for both men and women.
Serogroup B had significantly higher median IgG titres
compared to the C and I serogroups analysed in both
groups. Female group: B vs. C: p < 0.0001 (p: 2.0×10-6; 200
vs. <50); B vs. I: p < 0.0001 (p: 2.0×10-6; 200 vs. 50); male
Table 1 Median serological IgG titres in men and women subdivided by serogroup and serovar
Serogroup n % Median titre IgG Range Serovar n % Median titre IgG Range
Women (n = 510)
B 262 51.8 200* <50 – 3200 D/Da/D- 45 8.8 200 <50 – 3200
E 217 42.2 200 <50 – 1600
C 89 17.3 <50 <50 – 800 H 20 3.9 75 <50 – 800
I/Ia/I- 36 7.0 <50 <50 – 400
J 20 3.9 <50 <50 – 400
K 13 2.5 100 <50 – 800
I 159 30.9 50 <50 – 800 F 127 24.7 50 <50 – 800
G/Ga 32 6.2 100 <50 – 400
Men (n = 138)
B 66 47.8 150† <50 – 400 D/Da/D- 11 8.0 100 <50 – 400
E 55 39.9 200 <50 – 400
C 23 16.7 <50 <50 – 400 H 0 0.0 n/a n/a
I/Ia/I- 3 2.2 50 <50 – 50
J 12 8.7 <50 <50 – 200
K 8 5.8 75 <50 – 400
I 49 35.5 <50 <50 – 400 F 30 21.7 50 50 – 400
G/Ga 19 13.8 <50 <50 – 400
*: B-group significantly different from C and I group (p < 0.0001 and p < 0.0001) respectively. †: B-group significantly different from C and I group (p = 0.0006 and
p = 0.0001) respectively.
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(150 vs. <50). No significant differences were observed
between serogroups C and I. For women C vs. I: p = 0.14
(<50 vs. 50), for men C vs. I: p = 0.65 (<50 vs. <50).Serovar analyses
Table 1 shows the median IgG titres per serovar for both
women and men. At the serovar level in the female group,
serovars D and E demonstrated the highest median IgG,
followed by serovars K, H, G, and F. Serovars J and I
showed the lowest titres. In the Dutch male group sero-
vars D and E induced the highest median IgG titres,
followed by serovar G, K, F, J, and I. Serovar H was not
present in this group.In-group analyses
Within the serogroups, no difference was observed be-
tween serovars D and E in both men and women. For
females, median IgG titres in serovar J infected patients
were significantly lower compared to serovar K infected
patients (p = 0.029; <50 vs. 100). No differences were
observed between the other serovars of group C. In ser-
ogroup I (serovars F and G) no significant differences
were observed in median IgG titres. No differences in
serological responses were observed within the serogroups
for the male group.Discussion
This study shows that the most prevalent urogenital
C. trachomatis serogroup B causes the highest serological
IgG responses. More specifically, both serovars D and E of
the B serogroup show higher IgG serological responses
than the other serovars. Within serogroup C of the com-
bined Dutch female patient group, we found a small differ-
ence between serovar K and J. The results generated in
this study may be of clinical interest since an association
was observed between antibody response and severity of
tubal pathology in an earlier study [16].
We observed higher serological responses in women
compared to men for all serovars, but this did not reach
statistical significance. Eighty-two samples from Study 1
were unique compared to the previous study after
exclusion. These samples showed similar results as
compared to the earlier samples [17]. Compared to our
previous study [17] of 235 patients, we increased our
total study group to 648 patients and differentiated be-
tween men and women and confirmed our preliminary
results. Both of our studies were performed with the
medac ELISA assays. Interestingly, we observed similar
results in a group of C. trachomatis infected Danish
women (n = 91) using a different C. trachomatis-specific
serological IgG test (SeroCT IgG ELISA; Savyon Diag-
nostics Ltd., Ashdod, Israel) [23]; serogroup B serovars
induced the highest serological response compared to
the other serovars (unpublished data).
Figure 2 The figure shows the median titres for three serogroups in men and women, depicted as a boxplot. The upper and lower limit
of the box represents the first and third quartile. The cross represents the median of the group. The upper and lower limit of the range is
presented as horizontal bars on a vertical axis. The large range between upper and lower limits are mostly caused by single samples that might
be considered outliers. The distribution of the titres is best represented by the medians, and the first and third quartile limits.
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form equally in sensitivity and specificity for these STI
cohorts as we have previously shown [23]. Recently a
potentially new target for C. trachomatis serology has
been evaluated, but this assay is not yet commercially
available [24]. This pgp3 assay showed highest relevance
for titre positivity over time as compared to other com-
mercially available tests. In our study population no
follow-up samples were obtained. It would be of interest
to compare the pgp3 assay with the used medac assay
since about 30% of the samples had C. trachomatis DNA
present without a detectable serological response.
Current detection methods for C. trachomatis are based
on PCR techniques for DNA or RNA amplification. We
used two different methods for C. trachomatis detection
in this study and combined the results. However, the sen-
sitivities and specificities of the current detection methods
are very comparable, so no potential bias was introduced
[25]. We also used two different serovar determination
techniques. Quint et al. compared the C. trachomatis-DT
assay to sequencing of the VD2 region for C. trachomatisgenotyping. They found equal performances for both
methods, so no potential bias was introduced in this study
by making use of two different genotyping methods [26].
To gain more knowledge about differences in serological
IgG responses between serovars in humans, studies in
murine models and at cellular level may give more insight
in this biological mechanism. Ito et al. [27] suggested in
an earlier study that high serological responses in mice in-
duced by the B serogroup (D and E) may be caused by
longer antigenic stimulation, implicating that these high
responses just reflect duration of infection. Lyons et al.
[15] compared the cytotoxicity between the serovars D
and H. They found that serovar H is much more cytotoxic
than serovar D. Results of these studies suggested that ser-
ovars D and E (of the B serogroup) induce higher sero-
logical IgG responses in mice and have a longer duration
than the C and I serogroup serovars. In contrast, serovar
H is more cytotoxic than serovar D, but induces a lower
IgG titre in the murine model. Eckert et al. [28] studied
median IFU counts, a measure for virulence, in McCoy
cells inoculated with C. trachomatis infected human
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serovars B, D, and E induced the highest amount of IFU,
and serovars I and J induced the smallest amount of
IFU. This is a similar trend to what we find with regard
to the serological responses in our study population.
By using a large group of patients, this study confirmed
our previous results regarding serological responses and
based on the size of the study population we were also
able to link back to the serovar level [17]. Our results
bring us one step closer to understanding the immuno-
logical response against a C. trachomatis infection at both
serogroup and serovar level, and the variation in sero-
logical responses between women and men. From a clin-
ical point of view it would be interesting to identify a
relation between serological responses and C. trachomatis
serovars/serogroups. However, none of the limited human
studies performed on C. trachomatis serovars and the clin-
ical course of infection included serological responses,
making it currently impossible to translate our finding into
a direct application for the clinic [29-31]. The knowledge
generated in this study may aid in the development of
a vaccine against C. trachomatis infection for which
immunological responses to specific serovars linked to
the natural duration of infection might be useful.
Conclusions
In conclusion, this study shows that serogroup B induces
the highest serological responses compared to the other
serogroups. More specifically, serovars D and E show
higher serological responses than the other serovars.
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